Literature DB >> 24645687

Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer.

Joshua A Roth1, Mark E Bensink, Paul V O'Donnell, Ephraim J Fuchs, Mary Eapen, Scott D Ramsey.   

Abstract

BACKGROUND: BMT CTN 1101 is a Phase III randomized controlled trial evaluating the comparative effectiveness of double unrelated umbilical cord blood (dUCB) versus HLA-haploidentical related donor bone marrow (haplo-BM) donor cell sources for blood or bone marrow transplantation (BMT) in patients with hematologic malignancies. Herein, we present the rationale, design and methods of the first cost-effectiveness analysis to be conducted alongside a BMT trial.
METHODS: Consenting patients will provide health insurance information to allow calculation of direct medical costs from reimbursement records, and will provide out-of-pocket costs, time costs and health-related quality of life measures through an online survey. These outcomes will inform a cost-effectiveness analysis comparing dUCB and haplo-BM donor cell sources from patient, payer and societal perspectives.
CONCLUSION: Novel approaches may significantly change the cost, outcomes or availability of BMT. The results of this analysis will be the first to provide a comprehensive evaluation of the comparative effectiveness of these approaches from multiple perspectives.

Entities:  

Mesh：

Year:  2014        PMID： 24645687      PMCID： PMC4036637          DOI： 10.2217/cer.13.95

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN： 2042-6305            Impact factor:   1.744


  33 in total

1.  The estimation of a preference-based measure of health from the SF-36.

Authors:  John Brazier; Jennifer Roberts; Mark Deverill
Journal:  J Health Econ       Date:  2002-03       Impact factor: 3.883

2.  The validity and reproducibility of a work productivity and activity impairment instrument.

Authors:  M C Reilly; A S Zbrozek; E M Dukes
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

Review 3.  Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.

Authors:  Scott Ramsey; Richard Willke; Andrew Briggs; Ruth Brown; Martin Buxton; Anita Chawla; John Cook; Henry Glick; Bengt Liljas; Diana Petitti; Shelby Reed
Journal:  Value Health       Date:  2005 Sep-Oct       Impact factor: 5.725

Review 4.  Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant.

Authors:  Karen K Ballen; John Koreth; Yi-Bin Chen; Bimalangshu R Dey; Thomas R Spitzer
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

5.  Estimating the costs attributable to a disease with application to ovarian cancer.

Authors:  R Etzioni; N Urban; M Baker
Journal:  J Clin Epidemiol       Date:  1996-01       Impact factor: 6.437

6.  Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.

Authors:  Javier Bolaños-Meade; Juan Wu; Brent R Logan; John E Levine; Vincent T Ho; Amin M Alousi; Daniel J Weisdorf; Leo Luznik
Journal:  Biol Blood Marrow Transplant       Date:  2012-12-12       Impact factor: 5.742

Review 7.  Umbilical cord blood transplantation: pros, cons and beyond.

Authors:  Anfisa Stanevsky; Gal Goldstein; Arnon Nagler
Journal:  Blood Rev       Date:  2009-03-17       Impact factor: 8.250

8.  Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005.

Authors:  Amar Safdar; Gilhen H Rodriguez; Marcos J De Lima; Demetrios Petropoulos; Roy F Chemaly; Laura L Worth; Elizabeth J Shpall; Kenneth V I Rolston; Issam I Raad; Ka Wah Chan; Richard E Champlin
Journal:  Medicine (Baltimore)       Date:  2007-11       Impact factor: 1.889

9.  Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia.

Authors:  U Platzbecker; C Thiede; M Füssel; G Geissler; T Illmer; B Mohr; M Hänel; R Mahlberg; U Krümpelmann; F Weissinger; M Schaich; C Theuser; G Ehninger; M Bornhäuser
Journal:  Leukemia       Date:  2006-04       Impact factor: 11.528

10.  A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.

Authors:  A P Grigg; J Gibson; P G Bardy; J Reynolds; P Shuttleworth; R L Koelmeyer; J Szer; A W Roberts; L B To; G Kennedy; K F Bradstock
Journal:  Biol Blood Marrow Transplant       Date:  2007-02-22       Impact factor: 5.742
View more
  4 in total

Review 1.  The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation.

Authors: 
Journal:  Biol Blood Marrow Transplant       Date:  2016-07-11       Impact factor: 5.742

Review 2.  Administrative Claims Data for Economic Analyses in Hematopoietic Cell Transplantation: Challenges and Opportunities.

Authors:  Jaime M Preussler; Lih-Wen Mau; Navneet S Majhail; Christa L Meyer; Ellen M Denzen; Kristen C Edsall; Stephanie H Farnia; Alicia Silver; Wael Saber; Linda J Burns; David J Vanness
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-14       Impact factor: 5.742

Review 3.  Umbilical cord blood: The promise and the uncertainty.

Authors:  Tamila L Kindwall-Keller; Karen K Ballen
Journal:  Stem Cells Transl Med       Date:  2020-07-03       Impact factor: 6.940

Review 4.  Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic Disorders.

Authors:  Mohammad Faizan Zahid; David Alan Rizzieri
Journal:  Adv Hematol       Date:  2016-02-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.